Global pharma major Lupin Limited (Lupin) today announced that it has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA), Obeticholic Acid Tablets, 5 mg and 10 mg, to market a generic equivalent of Ocaliva® Tablets, 5 mg and 10 mg, of Intercept Pharmaceuticals, Inc.
Obeticholic Acid Tablets (RLD Ocaliva) had estimated annual sales of USD 255 million in the U.S. (IQVIA MAT December 2022).
Lupin shares
The shares of Lupin on Thursday closed at Rs 648.80, down by 1.53 per cent.
1993 Mumbai Bomb Blasts Case: 'Abu Salem Has Not Yet Completed 25-Year Sentence Under Extradition Terms,' Says Bombay HC
Bombay HC Rejects Plea To Set Up ICCs For Advocates Under POSH Act, Says Law Doesn’t Apply Without Employer-Employee Relationship
Bombay HC Issues Contempt Notices To BMC Officials For Demolishing Petitioner’s Home Despite Assurances
₹122 Crore New India Co-operative Bank Scam: Jharkhand Gang Promised Hitesh Mehta 50% Returns; ₹15 Cr Withdrawn Under Pre-Planned Strategy; Reveals EOW Probe
